Fly News Breaks for March 10, 2015
ADHD
Mar 10, 2015 | 10:02 EDT
Piper Jaffray found Alcobra's Phase II safety study of MDX in pediatric ADHD encouraging as it indicated MDX to be safe in the younger population. Piper points out the study was not powered for efficacy. It says pediatric ADHD remains a "free call" in its valuation model and reiterates an Overweight rating on Alcobra with a $21 price target.
News For ADHD From the Last 2 Days
There are no results for your query ADHD